Drug Trial Radar · NCT00832039
Placebo Controlled Trial of Sodium Selenite and Procalcitonin Guided Antimicrobial Therapy in Severe Sepsis
Last checked: Nov 20, 2026Latest source record: Aug 12, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,089
Actual
Start
Nov 2009
Primary completion
Mar 2013
Study completion Jun 2013
Sponsor
- Lead sponsor
- Kompetenznetz SepsisResearch network
- Sponsor type
- Research network
- Collaborators
- Biosyn; Brahms AG
- First posted
- Jan 29, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Severe sepsis and septic shock are diseases of infectious origin with a high risk of death. The purpose of this study is to determine whether the intravenous application of selenium (given as sodium-selenite) can reduce mortality in patients with severe sepsis or septic shock. Additionally, it is investigated, whether the measurement of procalcitonin - a marker of infection - can be used to guide anti-infectious measures in this disease.
Conditions
- Severe Sepsis
- Septic Shock
Interventions
sodium-seleniteDrug
An intravenous bolus of 1000 µg followed by a continuous intravenous infusion of 1000 µg/day until patient is discharged from the ICU but not more than 21 applications à 24 hours.
PlaceboDrug
An intravenous bolus of placebo followed by a continuous intravenous infusion with placebo until patient is discharged from the ICU but not more than 21 applications à 24 hours.
Procalcitonin guided therapyProcedure
Causal therapy of sepsis is guided by applying the following algorithm: Day 4: PCT drop from baseline \>=50%: no change in causal therapy; PCT drop from baseline \<50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control. Day 7, 10, 14: PCT \<=1.0 ng/ml: finish antimicrobial therapy; PCT \>1.0 ng/ml and PCT drop from last PCT measurement \>=50%: finish antimicrobial therapy; PCT \>1.0 ng/ml and PCT drop from last PCT measurement \<50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control.
Primary outcomes
What the sponsor says the trial is designed to measure.
- All cause mortalityTime frame: 28 days
Locations
35 sites in 1 country. Site status is shown where the registry gives one.
University Hospital Aachen - Dep. of Intensive Care Medicine
Aachen, Germany
Klinikum Augsburg - Dep. of Anesthesiology and Intensive Care Medicine
Augsburg, Germany
Klinikum Augsburg - Dep. of Medicine I
Augsburg, Germany
Military Hospital Berlin - Dep. of Anaesthesiology and Intensive Care Medicine
Berlin, Germany
Charité Berlin - Dep. of Anesthesiology and Intensive Care Medicine
Berlin, Germany
Vivantes Klinikum Neukölln - Dep. of Anesthesiology, Intensive Care Medicine and Pain Therapy
Berlin, Germany
DRK-Kliniken Berlin-Köpenick - Dep. of Anesthesiology, Pain Therapy, and Intensive Care Medicine
Berlin, Germany
Charité Berlin - Campus Virchow-Klinikum - Dep. of Nephrology
Berlin, Germany
Ev. Krankenhaus Gilead - Dep. of Anesthesiology
Bielefeld, Germany
University Hospital Bonn - Dep. of Anesthesiology and Intensive Care Medicine
Bonn, Germany
University Hospital Köln - Dep. of Medicine I
Cologne, Germany
Krankenhaus Dresden-Friedrichstadt
Dresden, Germany
University Hospital Dresden - Dep. of Anesthesiology and Intensive Care Med.
Dresden, Germany
HELIOS Klinikum Erfurt - Dep. of Anesthesiology and Intensive Care Medicine
Erfurt, Germany
University Erlangen-Nürnberg - Dep. of Medicine IV
Erlangen, Germany
J.-W. Goethe University Hospital - Dep. of Anaesthesiology, Intensive Care Medicine and Pain Therapy
Frankfurt am Main, Germany
University Hospital Freiburg- Dep. of Surgery
Freiburg im Breisgau, Germany
Georg August Universität Göttingen - Dep. of Anesthesiology and Intensive Care Medicine
Göttingen, Germany
Ernst-Moritz-Arndt-Universität Greifswald - Dep. of Anesthesiology and Intensive Care Medicine
Greifswald, Germany
Martin-Luther-Universität Halle-Wittenberg - Dep. of Anesthesiology
Halle, Germany
University Hospital Halle - Dep. of Medicine III
Halle, Germany
Universitätsklinikum Hamburg-Eppendorf - Dep. of Intensive Care Medicine
Hamburg, Germany
Westküstenklinikum Heide - Dep. of Anesthesiology and Intensive Care Medicine
Heide, Germany
University Hospital Heidelberg - study center Anesthesiology/Surgery
Heidelberg, Germany
University Hospital Jena, Dep. of Anesthesiology and Intensive Care Medicine
Jena, Germany
University Hospital Kiel - Dep. of. Anesthesiology and Intensive Care Medicine
Kiel, Germany
St. Elisabeth-Krankenhaus - Dep. of Anesthesiology
Köln-Hohenlind, Germany
University Hospital Leipzig - Dep. of Anesthesiology and Intensive Care Medicine
Leipzig, Germany
University Hospital Mannheim - Dep. of Medicine I
Mannheim, Germany
Krankenhaus München-Neuperlach - Dep. of Anesthesiology
München, Germany
University Hospital Munich - Dep. of Internal Medicine
Munich, Germany
University Hospital Munich - Dep. of Anaesthesiology
Munich, Germany
Hospital Munich Harlaching - Dep. of Internal Acute Medicine and Prevention
Munich, Germany
University Hospital Münster - Dep. of Anesthesiology and Intensive Care Medicine
Münster, Germany
Klinikum Oldenburg GmbH - Dep. of Anesthesiology
Oldenburg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.